Literature DB >> 19571804

Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.

J A Johnson1, Y Gong, K R Bailey, R M Cooper-DeHoff, A B Chapman, S T Turner, G L Schwartz, K Campbell, S Schmidt, A L Beitelshees, E Boerwinkle, J G Gums.   

Abstract

For combination antihypertensive therapy with thiazide diuretics and beta-blockers, the effect of the order of initiation of the drugs on the outcome has not been tested. Patients with uncomplicated hypertension were randomized to receive either hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by addition of the alternative drug. Blood pressure (BP) responses were evaluated by race and order of drug initiation. A total of 368 participants received combination therapy. Among the participants, blacks showed a greater BP-lowering effect than whites did with HCTZ monotherapy (-13.0/-7.4 mm Hg vs. -8.0/-4.2 mm Hg, P < 0.001) but a smaller BP-lowering effect than did whites with atenolol monotherapy (-1.1/-2.9 mm Hg vs. -9.9/-9.2 mm Hg, P < 0.0001). These differences were not evident during combination therapy. However, both groups showed greater response to HCTZ + atenolol than to atenolol + HCTZ (-19.1/-14.2 mm Hg vs. -15.6/-11.3 mm Hg, P < 0.0001). Despite optimal dosing of HCTZ + atenolol, only two-thirds of the participants achieved BP control. In HCTZ/atenolol combination antihypertensive therapy, the order in which the drugs are initiated affects total BP lowering during the first 4-6 months of therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571804      PMCID: PMC2765524          DOI: 10.1038/clpt.2009.101

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Blood pressure measuring devices: recommendations of the European Society of Hypertension.

Authors:  E O'Brien; B Waeber; G Parati; J Staessen; M G Myers
Journal:  BMJ       Date:  2001-03-03

2.  Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial.

Authors:  Y Imai; T Ohkubo; A Hozawa; I Tsuji; M Matsubara; T Araki; K Chonan; M Kikuya; H Satoh; S Hisamichi; K Nagai
Journal:  J Hypertens       Date:  2001-02       Impact factor: 4.844

3.  Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  I Scott; M Stowasser
Journal:  Intern Med J       Date:  2003-07       Impact factor: 2.048

4.  ALLHAT debate: diuretics are not preferred, first-line initial therapy for hypertension.

Authors:  Mark C Houston
Journal:  Arch Intern Med       Date:  2004-03-08

5.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

Review 6.  Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument against.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-02       Impact factor: 3.738

Review 7.  Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems.

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-17       Impact factor: 3.000

8.  Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy.

Authors:  George S Stergiou; Nikolaos M Baibas; Alexandra P Gantzarou; Irini I Skeva; Chrysa B Kalkana; Leonidas G Roussias; Theodore D Mountokalakis
Journal:  Am J Hypertens       Date:  2002-02       Impact factor: 2.689

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

10.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

View more
  8 in total

1.  Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.

Authors:  Maximilian T Lobmeyer; Liewei Wang; Issam Zineh; Stephen T Turner; John G Gums; Arlene B Chapman; Rhonda M Cooper-DeHoff; Amber L Beitelshees; Kent R Bailey; Eric Boerwinkle; Carl J Pepine; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2011-01       Impact factor: 2.089

Review 2.  Hypertension pharmacogenomics: in search of personalized treatment approaches.

Authors:  Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

3.  Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.

Authors:  Rhonda M Cooper-DeHoff; Sheron Wen; Amber L Beitelshees; Issam Zineh; John G Gums; Stephen T Turner; Yan Gong; Karen Hall; Vishal Parekh; Arlene B Chapman; Eric Boerwinkle; Julie A Johnson
Journal:  Hypertension       Date:  2009-11-16       Impact factor: 10.190

4.  Combination antihypertensive treatment: is initiation order important?

Authors:  John G Gums; Julie A Johnson
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08       Impact factor: 3.738

5.  Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.

Authors:  J D Duarte; S T Turner; B Tran; A B Chapman; K R Bailey; Y Gong; J G Gums; T Y Langaee; A L Beitelshees; R M Cooper-Dehoff; E Boerwinkle; J A Johnson
Journal:  Pharmacogenomics J       Date:  2012-02-21       Impact factor: 3.550

6.  Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.

Authors:  Julio D Duarte; Issam Zineh; Ben Burkley; Yan Gong; Taimour Y Langaee; Stephen T Turner; Arlene B Chapman; Eric Boerwinkle; John G Gums; Rhonda M Cooper-Dehoff; Amber L Beitelshees; Kent R Bailey; Roger B Fillingim; Bruce C Kone; Julie A Johnson
Journal:  J Transl Med       Date:  2012-03-22       Impact factor: 5.531

Review 7.  The current status of beta blockers' use in the management of hypertension.

Authors:  Shahid Akbar; Mohammad S Alorainy
Journal:  Saudi Med J       Date:  2014-11       Impact factor: 1.484

8.  Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.

Authors:  Ana Caroline C Sá; Amy Webb; Yan Gong; Caitrin W McDonough; Somnath Datta; Taimour Y Langaee; Stephen T Turner; Amber L Beitelshees; Arlene B Chapman; Eric Boerwinkle; John G Gums; Steven E Scherer; Rhonda M Cooper-DeHoff; Wolfgang Sadee; Julie A Johnson
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.